Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
What’s Bristol-Myers Squibb’s Plan B if its Celgene deal falls through? BMS won’t say whether it has one at all. And the company may be more likely to need a backup plan than some industry-watchers think. As Wolfe Research’s Tim Anderson pointed out in a note to clients, the company has so far skirted questions… Read More »